Nimotuzumab Completed Phase 3 Trials for Cervical Cancer Recurrent or Persistent / Palliative Treatment / Monoclonal Antibody in Cervical Cancer Treatment Treatment

Indications	Status	Purpose	Phase
DBCOND0069617 (Cervical Cancer Recurrent or Persistent) DBCOND0036546 (Palliative Treatment) DBCOND0069616 (Monoclonal Antibody in Cervical Cancer Treatment)	Completed	Treatment	3

clinicaltrials.gov Identifier	Title	Drugs
NCT02083211	Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma	Nimotuzumab (DB06192)